2024
Optimizing Opioid Prescription Quantity After Cesarean Delivery
Smid M, Clifton R, Rood K, Srinivas S, Simhan H, Casey B, Longo M, Landau R, MacPherson C, Bartholomew A, Sowles A, Reddy U, Rouse D, Bailit J, Thorp J, Chauhan S, Saade G, Grobman W, Macones G. Optimizing Opioid Prescription Quantity After Cesarean Delivery. Obstetrics And Gynecology 2024, 144: 195-205. PMID: 38857509, PMCID: PMC11257794, DOI: 10.1097/aog.0000000000005649.Peer-Reviewed Original ResearchOpioid tabletsCesarean birthOpioid useHuman Development Maternal-Fetal Medicine Units NetworkMaternal-Fetal Medicine Units NetworkPrimary outcomeQuantity of opioid tabletsEunice Kennedy Shriver National Institute of Child HealthOpioid prescription protocolPostcesarean pain managementHistory of opioid useOpioid prescription quantitiesRandomized controlled noninferiority trialNational Institute of Child HealthInstitute of Child HealthPostcesarean analgesiaCesarean deliveryRandomized controlled trialsPain managementPrescription quantitiesFollow-upWeeks postdischargeNoninferiority trialDecision makingChild health
2023
Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design
Metz T, Clifton R, Gallagher R, Gross R, Horwitz L, Jacoby V, Martin-Herz S, Peralta-Carcelen M, Reeder H, Beamon C, Chan J, Chang A, Costantine M, Fitzgerald M, Foulkes A, Gibson K, Güthe N, Habli M, Hackney D, Hoffman M, Hoffman M, Hughes B, Katz S, Laleau V, Mallett G, Mendez-Figueroa H, Monzon V, Palatnik A, Palomares K, Parry S, Pettker C, Plunkett B, Poppas A, Reddy U, Rouse D, Saade G, Sandoval G, Schlater S, Sciurba F, Simhan H, Skupski D, Sowles A, Thaweethai T, Thomas G, Thorp J, Tita A, Weiner S, Weigand S, Yee L, Flaherman V, Initiative O. Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design. PLOS ONE 2023, 18: e0285351. PMID: 38128008, PMCID: PMC10734909, DOI: 10.1371/journal.pone.0285351.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionSARS-CoV-2Long-term outcomesMonths of agePregnancy cohortMaternal-Fetal Medicine Units NetworkHealth outcomesSARS-CoV-2 antibody testingAdverse long-term outcomesEunice Kennedy Shriver National InstitutePost-acute sequelaeLong-term sequelaeClinical trial registrationMaternal-child dyadsNational InstituteMulti-site observational studyCalifornia San FranciscoUnique physiologic changesPregnancy modifiesMaternal infectionMultiple gestationsOverall cohortRetrospective cohortAntibody testingLong COVIDRisk Factors for Perinatal Transmission of Hepatitis C Virus
Prasad M, Saade G, Clifton R, Sandoval G, Hughes B, Reddy U, Bartholomew A, Salazar A, Chien E, Tita A, Thorp J, Metz T, Wapner R, Sabharwal V, Simhan H, Swamy G, Heyborne K, Sibai B, Grobman W, El-Sayed Y, Casey B, Parry S, Rathore M, Diaz-Velasco R, Puga A, Wiznia A, Kovacs A, Garry D, Macones G. Risk Factors for Perinatal Transmission of Hepatitis C Virus. Obstetrics And Gynecology 2023, 142: 449-456. PMID: 37590978, PMCID: PMC10437102, DOI: 10.1097/aog.0000000000005306.Peer-Reviewed Original ResearchConceptsPerinatal transmissionHCV infectionRisk factorsPrimary outcomeHuman Development Maternal-Fetal Medicine Units NetworkMaternal-Fetal Medicine Units NetworkHepatitis C virus infectionEunice Kennedy Shriver National InstituteC virus infectionPerinatal transmission rateWeeks of gestationHigh viral loadHepatitis C virusMonths of lifePositive test resultsAntepartum bleedingViremic participantsVaginal bleedingHCV RNAViremic individualsViral loadC virusObservational studyVirus infectionDemonstrable viremia
2016
Antenatal Betamethasone for Women at Risk for Late Preterm Delivery
Gyamfi-Bannerman C, Thom E, Blackwell S, Tita A, Reddy U, Saade G, Rouse D, McKenna D, Clark E, Thorp J, Chien E, Peaceman A, Gibbs R, Swamy G, Norton M, Casey B, Caritis S, Tolosa J, Sorokin Y, VanDorsten J, Jain L. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. Obstetrical & Gynecological Survey 2016, 71: 453-455. DOI: 10.1097/01.ogx.0000489576.69844.54.Peer-Reviewed Original ResearchLate preterm periodPreterm periodMaternal-Fetal Medicine Units NetworkEunice Kennedy Shriver National InstituteLate preterm deliveryAdministration of betamethasoneAntenatal betamethasoneNeonatal morbidityPreterm deliveryMulticenter trialClinical centersChildhood complicationsChild healthNational InstituteBetamethasoneWomenRiskMorbidityComplicationsNewbornsInfantsAdministrationTrials
2015
The association of beta‐2 adrenoceptor genotype with short‐cervix mediated preterm birth: a case–control study
Miller R, Smiley R, Thom E, Grobman W, Iams J, Mercer B, Saade G, Tita A, Reddy U, Rouse D, Sorokin Y, Blackwell S, Esplin, Tolosa J, Caritis, Network E. The association of beta‐2 adrenoceptor genotype with short‐cervix mediated preterm birth: a case–control study. BJOG An International Journal Of Obstetrics & Gynaecology 2015, 122: 1387-1394. PMID: 25600430, PMCID: PMC4508241, DOI: 10.1111/1471-0528.13243.Peer-Reviewed Original ResearchConceptsShort cervixCervical lengthAR genotypeMaternal-Fetal Medicine Units NetworkEunice Kennedy Shriver National InstituteNormal cervical lengthShort cervical lengthShort cervix groupPreterm birth riskCase-control studyRace/ethnicitySpontaneous PTBNulliparous womenPregnancy outcomesPreterm birthTransvaginal sonogramsPrimary outcomePTB riskSecond trimesterAncillary studiesChild healthBirth riskCervixAdrenoceptor genotypeControl group